A smartphone-assisted pressure-measuring-based diagnosis system for acute myocardial infarction diagnosis
Received 8 December 2018
Accepted for publication 15 February 2019
Published 8 April 2019 Volume 2019:14 Pages 2451—2464
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 2
Editor who approved publication: Dr Thomas Webster
Guolin Hong,1 Gang Rui,2 Dongdong Zhang,1 Mingjian Lian,1 Yuanyuan Yang,1 Ping Chen,1 Huijing Yang,3 Zhichao Guan,4 Wei Chen,5 Yan Wang6
1Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China; 2Department of Orthopaedic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China; 3Department of Clinical Medicine, Fujian Medical University, Fuzhou 350108, People’s Republic of China; 4Department of Research and development, Xiamen Passtech Co.,Ltd., Xiamen 361101, People’s Republic of China; 5Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, Fujian Medical University, Fuzhou 350004, People’s Republic of China; 6Department of Cardiology, the Affiliated Cardiovascular Hospital of Xiamen University, Medical College of Xiamen University, Xiamen 361004, People’s Republic of China
Background: Acute myocardial infarction (AMI), usually caused by atherosclerosis of coronary artery, is the most severe manifestation of coronary artery disease which results in a large amount of death annually. A new diagnosis approach with high accuracy, reliability and low measuring-time-consuming is essential for AMI quick diagnosis.
Purpose: The objective of this study was to develop a new point-of-care testing system with high accuracy and reliability for AMI quick diagnosis.
Patients and methods: 50 plasma samples of acute myocardial infarction patients were analyzed by developed Smartphone-Assisted Pressure-Measuring-Based Diagnosis System (SPDS). The concentration of substrate was firstly optimized. The effect of antibody labeling and matrix solution on measuring result were then evaluated. And standard curves for cTnI, CK-MB and Myo were built for clinical sample analysis. The measuring results of 50 clinical samples were finally evaluated by comparing with the measuring result obtained by CLIA.
Results: The concentration of substrate H2O2 was firstly optimized as 30% to increase measuring signal. A commercial serum matrix was chosen as the matrix solution to dilute biomarkers for standard curve building to minimize matrix effect on the accuracy of clinical plasma sample measuring. The standard curves for cTnI, CK-MB and Myo were built, with measuring dynamic range of 0–25 ng/mL, 0–33 ng/mL and 0–250 ng/mL, and limit of detection of 0.014 ng/mL, 0.16 ng/mL and 0.85 ng/mL respectively. The measuring results obtained by the developed system of 50 clinical plasma samples for three biomarkers matched well with the results obtained by chemiluminescent immunoassay.
Conclusion: Due to its small device size, high sensitivity and accuracy, SPDS showed a bright potential for point-of-care testing (POCT) applications.
Keywords: acute myocardial infarction, diagnosis, pressure sensor, smartphone, Pt nanoparticle
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]